Effect of community pharmacist intervention on cholesterol levels in patients at high risk of cardiovascular events: the second study of cardiovascular risk intervention by pharmacists (SCRIP-plus) - 25/08/11
, Kari L Olson, BSc(Pharm), PharmD a, Alexander M Dubyk, BSc(Pharm), PharmD a, Terri J Schindel, BSP, MCE c, Jeffrey A Johnson, BSP, PhD bEsquema
| Sponsored by unrestricted grants from Merck Frosst Canada Ltd, Pfizer Canada Ltd, and Pharmasave Drugs (National) Ltd. The sponsors had no role in the design and conduct of the study, or in the analysis or interpretation of the data. Dr. Johnson holds a Canada Research Chair in Diabetes Health Outcomes and is a Population Health Investigator with the Alberta Heritage Foundation for Medical Research. |
Vol 116 - N° 2
P. 130-133 - janvier 2004 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?
